Aligos Therapeutics, Inc. (ALGS) Key Metrics
ALGS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $30.3M
- Enterprise value
- $7.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.0 10-yr median 42.1
- Price / book
- 1.1
- EV / EBITDA
- 0.6
- Dividend yield
- —
- Beta
- 2.36
ALGS key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsALGS valuation Price multiples at each fiscal year-end price.
ALGS returns How much profit the business earns on the capital it uses.
ALGS per-share figures Results divided by the shares outstanding at year-end.
ALGS financial health Debt, liquidity and how easily interest is covered.
ALGS efficiency & capital use Working capital cycle and where the cash goes.
ALGS valuation history
ALGS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALGS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALGS price vs earnings per share
ALGS key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $92.1M | $249.6M | $412.9M | — | — | — | — | — |
| Enterprise value | $19.5M | $201.0M | $288.3M | — | — | — | — | — |
| Price / sales | 42.1 | 63.3 | 26.6 | — | — | — | — | — |
| Price / book | 1.7 | — | 4.5 | — | — | — | — | — |
| EV / sales | 8.9 | 51.0 | 18.6 | — | — | — | — | — |
| Earnings yield | −26.3% | −52.6% | −21.2% | — | — | — | — | — |
| Free cash flow yield | −90.0% | −32.4% | −19.1% | — | — | — | — | — |
| Share price at fiscal year-end | $9.32 | $39.84 | $16.60 | $23.82 | $296.75 | $691.25 | — | — |
| Per share | ||||||||
| Revenue per share | $0.22 | $0.63 | $0.62 | — | — | — | $0.00 | $0.00 |
| Earnings per share | −$2.45 | −$20.94 | −$3.52 | — | — | — | −$2.38 | −$0.66 |
| Operating cash flow per share | −$8.35 | −$12.89 | −$3.18 | — | — | — | −$2.13 | −$0.29 |
| Free cash flow per share | −$8.39 | −$12.91 | −$3.18 | — | — | — | −$2.26 | −$0.40 |
| Cash per share | $7.87 | $9.09 | $5.46 | — | — | — | $5.37 | $4.29 |
| Book value per share | $5.42 | −$4.62 | $3.70 | — | — | — | −$2.96 | −$0.65 |
| Tangible book value per share | $5.42 | −$4.62 | $3.70 | — | — | — | −$2.96 | −$0.65 |
| Capex per share | $0.04 | $0.02 | $0.00 | — | — | — | $0.13 | $0.12 |
| Debt per share | $0.53 | $1.34 | $0.45 | — | — | — | $0.65 | $0.65 |
| Shares outstanding | 9.9M | 6.3M | 24.9M | — | — | — | 21.9M | 21.2M |
| Change in shares outstanding | +57.8% | −74.8% | — | — | — | — | +3.6% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −196.9% | — | −89.5% | −66.6% | −63.4% | −139.9% | — | — |
| Return on assets (ROA) | −30.5% | −118.4% | −58.8% | −50.3% | −51.3% | −52.7% | −41.1% | −12.9% |
| Return on tangible assets | −27.3% | −187.2% | −57.9% | −65.5% | −54.5% | −40.9% | −35.7% | −12.9% |
| Free cash flow margin | — | — | −508.8% | −577.6% | — | — | — | — |
| Financial health | ||||||||
| Total debt | $5.2M | $8.4M | $11.1M | $12.6M | $14.5M | $13.0M | $14.3M | $13.9M |
| Cash & short-term investments | $77.8M | $56.9M | $135.7M | $125.8M | $190.7M | $243.5M | $117.7M | $90.9M |
| Net debt | −$72.6M | −$48.6M | −$124.6M | −$113.3M | −$176.3M | −$230.5M | −$103.3M | −$77.0M |
| Debt / equity | 0.10 | — | 0.12 | 0.12 | 0.08 | 0.06 | — | — |
| Debt / assets | 0.06 | 0.12 | 0.07 | 0.09 | 0.06 | 0.05 | 0.10 | 0.13 |
| Current ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Quick ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Interest coverage | — | — | — | -59.5 | -972.1 | -9.3 | -29.0 | — |
| Working capital | $61.6M | $40.4M | $117.2M | $100.4M | $165.5M | $219.7M | $106.4M | $84.9M |
| Invested capital | −$19.0M | −$77.5M | −$32.5M | −$9.4M | $8.5M | −$10.5M | −$168.2M | −$90.7M |
| Tangible asset value | $53.5M | −$29.0M | $92.1M | $103.9M | $184.7M | $220.0M | −$64.9M | −$13.7M |
| Net current asset value | $47.9M | −$36.9M | $81.6M | $90.8M | $153.8M | $204.8M | −$91.2M | −$29.1M |
| Graham net-net per share | $4.34 | −$6.72 | $3.07 | — | — | — | −$4.27 | −$1.45 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — |
| Capex / revenue | 20.0% | 3.3% | 0.1% | 6.8% | 20.5% | — | — | — |
| Capex / depreciation | 0.47 | 0.05 | 0.01 | 0.26 | 0.24 | 0.62 | 1.21 | 1.95 |
| Stock-based compensation / revenue | 230.7% | 214.2% | 81.5% | 105.7% | 308.7% | — | — | — |
| R&D / revenue | 3,177.2% | 1,781.2% | 470.3% | 611.8% | 2,389.4% | — | — | — |
| SG&A / revenue | 947.8% | 578.7% | 197.2% | 189.9% | 654.4% | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 1,285.9 | 354.1 | 431.4 | 385.0 | 11.1 | 388.6 | 535.4 | 841.7 |
| Payables turnover | 0.28 | 1.03 | 0.85 | 0.95 | 32.92 | 0.94 | 0.68 | 0.43 |
| Asset turnover | 0.03 | 0.04 | 0.10 | 0.07 | 0.02 | 0.00 | 0.00 | 0.00 |
| Average payables | $3.3M | $2.5M | $3.6M | $3.9M | $3.2M | $3.5M | $3.4M | $3.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ALGS's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALGS valuation and financial ratios
Aligos Therapeutics earned a return on equity of −196.9% in fiscal 2025. It ended the year with $5.2 million of debt and $77.8 million in cash and short-term investments, a net cash position of $72.6 million. The share count fell 53.3% from 21.2M to 9.9M over 7 years.
See the ALGS income statement, the ALGS chart for price history, or the ALGS stock overview for the latest quote and news.
ALGS key metrics FAQ
What is Aligos Therapeutics's return on equity?
Aligos Therapeutics's return on equity (ROE) was −196.9% in fiscal 2025: net income of -$24.2 million on average shareholders' equity of $12.3 million.
How much debt does Aligos Therapeutics have?
Aligos Therapeutics had total debt of $5.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
What is Aligos Therapeutics's free cash flow yield?
Aligos Therapeutics generated -$82.9 million of free cash flow in fiscal 2025, a free cash flow yield of −90.0% on its market value at year-end ($92.1 million).
What is Aligos Therapeutics's current ratio?
Aligos Therapeutics's current ratio was 3.90 at the end of fiscal 2025: current assets were 3.90 times current liabilities.